The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Co-administration of an ACE-inhibitor (moexipril) and hormonal replacement therapy in postmenopausal women
Co-administration of antihypertensive drug therapy and hormonal replacement therapy ( HRT ) is frequent in postmenopausal women but it is not known whether HRT interacts with concomitant antihypertensive therapy . The present study was design ed to investigate efficacy and safety of the ACE inhibitor moexipril in comparison to placebo in hypertensive , postmenopausal women on HRT . After a 4-week placebo run-in phase , 95 postmenopausal women ( 35–74 years of age ) who had a sitting diastolic blood pressure ( BP ) of 95–114 mm Hg and were treated with HRT were r and omised to a 12-week treatment with moexipril 15 mg or placebo .  Efficacy and safety were assessed by measuring changes in sitting BP and metabolic parameters associated with cardiovascular disease including triglycerides , total cholesterol , HDL , LDL , total cholesterol/HDL ratio and glucose . Adverse events were recorded continuously . After 12 weeks of treatment , moexipril 15 mg was significantly more effective in reducing sitting systolic and diastolic BP from baseline than placebo ( −12.2/ −9.9 mm Hg vs −1.6/−4.3 mm Hg , P < 0.001 ) . metabolic parameters were not affected by treatment with moexipril  : mean levels of triglycerides , total cholesterol , hdl , ldl , total cholesterol/hdl ratio and glucose remained unchanged throughout the study . fibrinogen , an independent cardiovascular risk factor , increased after placebo ( + 35.0 mg/dl ) and decreased after treatment with moexipril ( −33.6 mg/dl ) , the difference , however , was not statistically significant .  moexipril  was well-tolerated by postmenopausal women using hrt . the most frequent adverse events included headache ( 21.3 % ) , cough ( 12.8 % ) and rhinitis ( 10.6 % ) and there were no significant differences in the number and severity of adverse events between the moexipril and placebo groups . this study indicates that moexipril is effective and well tolerated in the treatment of hypertensive , postmenopausal women and can safely be co-administered to hrt
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .